StockNews.AI
VRNA
StockNews.AI
187 days

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

1. Verona Pharma will report Q4 and full year 2024 results on February 27. 2. The conference call will discuss financial results and corporate updates. 3. Ensifentrine is Verona's first product targeting chronic respiratory diseases.

Earnings
+3.25%Current Return
VS
+0.99%S&P 500
$62.702/13 06:03 AM EDTEvent Start
$64.7402/14 12:39 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming financial results usually lead to speculative trading. The impact largely depends on the performance relative to expectations.

How important is it?

Financial results can significantly influence stock price. Given VRNA's development stage, results are crucial.

Why Short Term?

Price action may fluctuate around the earnings release date. A strong or weak report could impact sentiment quickly.

Related Companies

COPDCFASTHMA
February 13, 2025 06:00 ET  | Source: Verona Pharma plc LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-836-8184 for callers in the United States+1-646-357-8785 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days. For further information please contact: About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

Related News